Hypofractionated whole breast IMRT with HDR brachytherapy boost in early-stage breast cancer: Long-term results from a single-center.
Ana Aurora Díaz-GavelaElia Del Cerro PeñalverSofía Sanchez-GarciaEduardo Pardo-PerezIsrael John Thuissard-VasalloCristina Andreu-VázquezMaría Yolanda Molina LópezMarina Pena HuertasLuis Leonardo Guerrero-GómezDavid Sanz-RosaFelipe Counago LorenzoPublished in: Brachytherapy (2024)
Adjuvant hypofractionated whole-breast IMRT followed by a single dose HDR-BT boost has a low incidence of acute and chronic toxicity and excellent oncological outcomes. However, it may be worthwhile to intensify self-care protocols and surveillance in women with large breasts who may be at increased risk of side effects.
Keyphrases
- early stage
- radiation therapy
- liver failure
- high dose
- public health
- drug induced
- risk factors
- oxidative stress
- respiratory failure
- sentinel lymph node
- locally advanced
- rectal cancer
- radical prostatectomy
- prostate cancer
- small cell lung cancer
- robot assisted
- low dose
- hepatitis b virus
- metabolic syndrome
- adipose tissue
- type diabetes
- insulin resistance
- minimally invasive
- acute respiratory distress syndrome